


**Product Name** : Iguratimod  
**Cat. No.** : PC-45134  
**CAS No.** : 123663-49-0  
**Molecular Formula** : C<sub>17</sub>H<sub>14</sub>N<sub>2</sub>O<sub>6</sub>S  
**Molecular Weight** : 374.3679  
**Target** : NF-κB  
**Solubility** : 10 mM in DMSO



## Biological Activity

Iguratimod (TT-614) is an antirheumatic agent that acts as an inhibitor of **COX-2** with IC<sub>50</sub> of 20 μM, does not inhibit COX-1, also inhibits macrophage **migration inhibitory factor** (MIF) with IC<sub>50</sub> of 6.81 μM.

Iguratimod (TT-614) is a disease-modifying antirheumatic drug that inhibits NF-kappaB (NF-κB) p65 subunit (RelA) phosphorylation and nuclear translocation without affecting IκBα degradation.

Iguratimod (TT-614) inhibits LPS-stimulated production of TNF-α, IL-6, and IL-8 with decreasing mRNA levels (IL-6 and IL-8). Iguratimod (TT-614) mainly targets Act1 to disrupt the interaction between Act1 and TRAF5 and IKKι in the IL-17 pathway of synoviocytes.

Iguratimod (TT-614) also exhibits selective MIF inhibition in vitro and in vivo.

## References

Luo Q, et al. *J Immunol*. 2013 Nov 15;191(10):4969-78.

Bloom J, et al. *J Biol Chem*. 2016 Dec 16;291(51):26502-26514.

Aikawa Y, et al. *Inflamm Res*. 2002 Apr;51(4):188-94.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com